Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...
Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio
Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% ...
Globus Medical reaffirms FY25 stand-alone EPS $3.40-$3.50, consensus $3.47
On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per ...
FierceBiotech1d
Globus Medical to buy neurostim developer Nevro for $250M
Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...
Globus Medical to buy Nevro in $250M all-cash deal
Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.
MassDevice4d
Globus Medical to acquire Nevro for $250M
Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).
Zacks.com on MSN18h
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain?
Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...
medtechdive5d
Globus to buy Nevro for $250M
Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...
Nasdaq5d
Globus Medical to Acquire Nevro Corp. in All-Cash Transaction Valued at $250 Million
Globus Medical reported preliminary sales projections for 2024 of $2.52 billion, while Nevro expects revenues between $408 million to $409 million. Globus Medical's acquisition of Nevro will ...